Cancer vaccine demonstrates early success against difficult-to-treat tumors
Researchers at UCLA and collaborators are testing a new off-the-shelf cancer vaccine, ELI-002 2P, that doesn’t require personalization and can be given to any patient whose tumor carries certain KRAS mutations. These mutations are common in about 90% of pancreatic cancers and roughly half of colorectal cancers. The peptide-based vaccine is designed to prime the immune system to recognize and attack KRAS-mutated cancer cells, offering a potentially more accessible and cost-effective alternative to highly tailored immunotherapies.
In a Phase 1 trial called AMPLIFY-201, 25 patients who had undergone surgery and had minimal residual disease — 20 with pancreatic cancer and five with colorectal cancer — received the vaccine. It combined peptides representing common KRAS mutations with an immune-stimulating adjuvant, CpG-7909, delivered to target lymph nodes. Over a median follow-up of nearly 20 months, 17 participants developed strong immune responses. These patients experienced markedly improved outcomes: median relapse-free survival and overall survival were not yet reached, compared to roughly three months and 16 months, respectively, for those with weaker responses. Only four of the strong responders died versus seven of the eight weak responders.
While the findings are early, they suggest that ELI-002 2P can safely train the immune system to fight KRAS-driven cancers. “Targeting KRAS has long been considered a difficult challenge in cancer therapy,” said Dr. Zev Wainberg, the study’s first author. “This vaccine offers a promising way to generate precise, durable immune responses without the complexity or cost of fully personalized approaches.” Further research in larger, controlled trials will be necessary to confirm the results.
Comments
Post a Comment